...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The New England journal of medicine >Bevacizumab for retinopathy of prematurity.
【24h】

Bevacizumab for retinopathy of prematurity.

机译：贝伐单抗用于早产儿视网膜病变。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In response to the article by Mintz-Hittner et al.: we note that bevacizumab (an anti-vascular endothelial growth factor [VEGF] agent) is already being used as first-line or rescue treatment for retinopathy of prematurity in many middle and emerging economies. In these settings, the population of babies with severe disease is very different from that in industrialized countries because more mature babies (gesta-tional age of >31 wk) are also often affected.1 This phenomenon has been termed the "third epidemic" of retinopathy of prematurity.2 Angio-genesis is still active in many organs of these babies at the time of treatment of retinopathy of prematurity, yet the potential risks of anti-VEGF agents may not be fully explained to parents, and access to medical legal redress is limited. It is imperative that the pharmacodynamics and safety profile of bevacizumab (or alternative agents) in the premature infant with acute retinopathy of prematurity and breakdown of the blood-ocular barrier be better delineated.3 Randomized clinical trials that are adequately powered to detect adverse events and that have sufficiently long follow-up to assess neurodevelopmental outcomes are urgently needed. Until that time we would advocate that anti-VEGF medications be used only when laser photocoagulation fails and when informed consent is rigorously obtained.
机译：针对Mintz-Hittner等人的文章：我们注意到贝伐单抗（一种抗血管内皮生长因子[VEGF]药物）已被用作许多中部和新兴的早产儿视网膜病变的一线治疗或抢救治疗经济。在这些情况下，重病婴儿的数量与工业化国家的人口数量有很大不同，因为更成熟的婴儿（胎龄超过31周）也经常受到影响。1这种现象被称为“第三流行病”。 2早产儿视网膜病变的治疗时，这些婴儿的许多器官中血管生成仍很活跃，但抗VEGF药物的潜在风险可能尚未向父母充分解释，并且无法获得医学上的法律补救是有限的。至关重要的是，应更好地描述贝伐单抗（或替代药物）在患有早产儿急性视网膜病变和血-眼屏障破坏的早产儿中的药效学和安全性。3有足够能力检测不良事件和不良反应的随机临床试验。迫切需要进行足够长时间的随访以评估神经发育结果。在此之前，我们提倡仅在激光光凝失败和严格获得知情同意的情况下使用抗VEGF药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号